Clinical trials: Injections
Multiple Myeloma
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma.
- Trial name
- NCT00097981
- Testing
- Thalidomide, Dexamethasone, DOXIL
- Where
- 58 sites in United States
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Radicular; Neuropathic, Cervical, Neck Pain
C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain
Cervical radicular pain is a common, disabling problem, occurs in 83:100,000 individuals per year. Symptoms are most often caused by intervertebral disc herniation (21.9%) or central or foraminal stenosis from spondylosis…
- Trial name
- NCT02095197
- Testing
- Triamcinolone 80mg
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Northwestern University
Bladder Cancer, Urothelial Carcinoma
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer
- Trial name
- NCT03636256
- Testing
- NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- NanOlogy, LLC
Type 2 Diabetes Mellitus
The Effectiveness of Intervention on Insulin Injection
The aim of the study is to assess the effectiveness of an intervention for insulin injection initiation based on the Transtheoretical Model (TTM) for insulin-naïve patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03324451
- Testing
- TTM Intervention for Insulin Initiation, Usual care
- Where
- Taiwan
- Volunteers
- 151 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Coronary Artery Disease
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography…
- Trial name
- NCT01347710
- Testing
- Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
- Where
- 81 sites in United States, Canada and 2 more
- Volunteers
- 795 people
- Sponsor
- Lantheus Medical Imaging
Tetanus, Acellular Pertussis
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00148941
- Testing
- SB213503 lot 1, SB213503 lot 2, SB213503 lot 3
- Where
- 24 sites in United States
- Volunteers
- 4,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
To demonstrate that a single dose of Makena® delivered SQ via auto-injector has comparable bioavailability to a single IM injection of Makena®.
- Trial name
- NCT02940522
- Testing
- Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Where
- 5 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Anesthesia
Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery
This is a multicenter, randomized, double-blinded, propofol-controlled, Phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery.
- Trial name
- NCT04711837
- Testing
- HSK3486, Propofol
- Where
- 13 sites in United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Haisco-USA Pharmaceuticals, Inc.
Lateral Canthal Lines
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
- Trial name
- NCT03911102
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Revance Therapeutics, Inc.
Pain Management
Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?
The purpose of the study is to determine the effect of a single injection adductor canal block (ACB) on pain scores within 24 hours post total knee arthroplasty (TKA).
- Trial name
- NCT02276495
- Testing
- ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of California, Irvine
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels.
- Trial name
- NCT02703337
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Infertility
To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)
Clinical trial objectives are to investigate the efficacy and safety of a single injection of 100 μg Org 36286 in women weighing 60 kg or less to induce multifollicular development for controlled ovarian stimulation (COS), using…
- Trial name
- Ensure (NCT00702845)
- Testing
- corifollitropin alfa (Org 36286), recFSH (follitropin beta), gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
- Volunteers
- 397 people
- Sponsor
- Organon and Co
Cardiomyopathy Due to Anthracyclines
Stem Cell Injection in Cancer Survivors
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction…
- Trial name
- SENECA (NCT02509156)
- Testing
- Allo-MSCs
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- The University of Texas Health Science Center, Houston
Healthy
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
This study is conducted to compare how much mirikizumab, in two different formulations, is absorbed into the bloodstream and how long the body takes to get rid of it, when given as an injection under the skin or into the veins.
- Trial name
- NCT03053622
- Testing
- Mirikizumab Test, Mirikizumab Reference
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
- Trial name
- NCT02634320
- Testing
- Aripiprazole Lauroxil
- Where
- 18 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alkermes, Inc.
Glabellar Lines
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin.
- Trial name
- NCT05248893
- Testing
- AGN-151586
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 992 people
- Sponsor
- AbbVie
Hypothyroidism
Thyroid Function of Pediatric Subjects Following Isovue® Administration
This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the…
- Trial name
- NCT03779906
- Testing
- Isovue
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bracco Diagnostics, Inc
Ankylosing Spondylitis
Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with ankylosing spondylitis
- Trial name
- NCT01248793
- Testing
- Golimumab
- Where
- 7 sites in China
- Volunteers
- 213 people
- Sponsor
- Centocor, Inc.
Follicular Lymphoma, Small Lymphocytic Lymphoma
Imexon for Relapsed Follicular and Aggressive Lymphomas
The purpose of this study is to determine whether Amplimexon (imexon for injection) is effective in the treatment of indolent and aggressive lymphomas that have progressed after treatment with standard therapies.
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma
- Trial name
- ULYM11011 (NCT01314014)
- Testing
- Imexon
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Rochester
Acromegaly
Ultrasound Guided Octreotide LAR Injection in Acromegaly
Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR.
- Trial name
- NCT00552071
- Testing
- Octreotide LAR 30 MG Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cedars-Sinai Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.